Printer Friendly

MiTiHeart Corporation to Present at Windhover Information and Medtech Insight's ``Investment In Innovation'' Conference.

BOSTON -- MiTiHeart Corporation will be presenting on Thursday, October 21, at Windhover Information and Medtech Insight's Prestigious "Investment In Innovation" Event, taking place October 21-22, at the Westin Copley Place Hotel in Boston.

MiTiHeart(R) Corporation is dedicated to developing and marketing unique blood pumps for patients suffering from congestive heart failure. The Company's blood pump, MiTiHeart(R) LVAD, has been in development since 1995, and a total of $12 million has been invested to date to establish the efficacy of the prototype blood pump and has significantly reduced the technical risks. The performance of the prototype pump has been evaluated in the laboratory and in a 200-hour animal test in collaboration with the Hershey Medical Center. The Company is currently seeking equity capital to finalize the design and conduct further pre-clinical tests that are needed prior to filing an application with the FDA for clinical evaluations.

According to the American Heart Association, approximately 4.5 million Americans have congestive heart failure (CHF) and nearly half a million new cases are reported every year. CHF is a chronic condition in which at least one chamber of the heart is not pumping well enough to meet the body's need. While effective pharmacologic therapies have improved outcomes for mild to moderate CHF, the need for mechanical circulatory support is well defined and growing. It is estimated that at least 100,000 patients annually in the U.S. could benefit from fully implantable blood pumps, as provided by MiTiHeart(R). These mechanical devices are connected to the weak left ventricle of the heart and assist the pumping action by forcing blood from the ventricle to the aorta. As such, the term left ventricular assist device (LVAD) is used to describe these pumps. Recently the Centers for Medicare and Medicaid Services agreed to offer reimbursements for implantation of LVADs for long-term use. This decision has established an expanding market for treatment of heart failure with these devices. It is estimated by Merril Lynch that the present $150 million U.S. market will grow at 22% per year to reach the projected market opportunity of $8 billion, followed by further annual growth rates of 12% to 15%.

The MiTiHeart(R) LVAD is based on a patented magnetically suspended rotary pump design and has many advantages over competing designs, including extremely low blood damage, a low potential for blood clot formation, low power consumption, minimal heat generation inside the pump, no contacting surfaces, and long life. There are also several built-in redundancies and safety features in the MiTiHeart(R) LVAD.

About Medtech Insight

Medtech Insight's "Investment In Innovation" conferences are considered the premier forum for senior executives in the investment and medical technology community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. Medtech Insight, which was recently acquired by Windhover Information Inc. (www.windhover.com), publisher of IN VIVO: The Business & Medicine Report, Start-UP: Windhover's Review of Emerging Technologies, and IN VIVO EuropeRx, offers a wide variety of products and services for the medical technology executive. In addition to conferences, the company publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, as well as analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the Boston conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail sales@medtechinsight.com, or visit http://www.medtechinsight.com/in3-12.html.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 1, 2004
Words:587
Previous Article:Cytec to Acquire Surface Specialties Business of UCB for EUR 1.5 Billion.
Next Article:ASIS International Joins the National Cyber Security Alliance; Will Promote October as National Cyber Security Awareness Month.


Related Articles
Windhover Information and Medtech Insight Announce the Next 'Investment In Innovation: A Preview of Early-Stage Medical Technology Companies'...
30 Early-Stage Medtech Companies Already Confirmed to Present at Windhover Information and Medtech Insight's Emerging Medical Technology Investment...
Leading VCs Look to Medtech Insight's 'Investment In Innovation' Conference for Maximum Exposure to High-Caliber Early-Stage Medical Technology...
Windhover Information (Norwalk, CT), a provider of information and services for the pharmaceutical, biotech and medical device industries, has...
59 Emerging Medical Technology Companies Confirmed to Present at Medtech Insight and Windhover Information's 'Investment In Innovation' Conference.
Medtech Insight and Windhover Information's 'Investment In Innovation' Medical Technology Investment Conference to Feature Interactive Panel...
Viking Systems, Inc. CEO Tom Marsh Invited to Present at Windhover Information and Medtech Insight's ``Investment In Innovation'' Conference.
Biowave Corporation to Present at Windhover Information and Medtech Insight's 'Investment in Innovation' Conference.
Cordeus, Inc. to Present at Windhover Information and Medtech Insight's 'Investment In Innovation' Conference.
European Medical Device Start-Up Industry is Poised for Tremendous Growth, According to Medtech Insight and Windhover Information.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters